Organic Active Ingredients TRIZ Cases

Cell-based assays evaluate cytidine and uridine nucleoside combinations that suppress HCV polymerase and RNA replication synergistically.

Sequential distillation and liquid-liquid extraction separate CBG regioisomers and impurities without costly chromatography.

Cysteamine inhibits glycine decarboxylase to reduce viral load and protect host cells.

This case uses small molecules to block RING1B-BMI1 E3 ligase activity and target leukemia stem cells resistant to chemotherapy.

Micronized rivaroxaban and HPMC capsules avoid wet granulation and improve stability.

This case uses hydrophilic and drug-affinity additives to improve rapid tissue delivery while avoiding oils and iodinated contrast agents.

This case combines HPMC and sodium alginate to reduce pH dependence, stabilize release, and help maintain blood glucose overnight.

This case uses substituted pyrazoles to inhibit IDO, limit immunosuppressive tryptophan degradation, and support T-cell activation.

Selective 2′-F and 2′-OMe placement in RNAi duplexes supports stability and gene silencing while limiting toxicity.

This injectable composition sustains tacrolimus release for 7 to 28 days, helping reduce absorption variability and dosing frequency.

Substituent and ring optimization targets KRAS G12D, addressing limited selectivity, toxicity, and bioavailability in existing inhibitors.

This case replaces costly multi-step chemistry with engineered microbes that control glycosylation for scalable LNT and LNnT production.

Solvation and stirring produce Emraclidine crystal forms that preserve purity under humidity and mechanical stress.

This case uses tailored substituents to target JAK1 and reduce off-target toxicity linked to JAK2/JAK3 inhibition.

This case combines a cephem oxime linkage and hydroxylated aromatic ring to improve iron chelation and antibacterial efficacy.

Defined extract and polyphenol ranges support self-applied formulations for inflammation, pigmentation, acne, and wound healing.

Oral propionic acid is absorbed too early; this composition uses Propionibacterium freudenreichii to generate it in the colon.

A defined Lactobacillus cocktail maintains acidic pH, inhibits pathogens, and stabilizes vaginal flora for BV prevention.

This case develops halogenated halo-allylamines that selectively target SSAO/VAP-1 while reducing side effects and nervous-system toxicity.

Modular azole-fused pyridazin-3(2H)-one derivatives act as GPR139 agonists for schizophrenia, depression, and related CNS disorders.

Formula (I) heteroaryl-biphenyl amines address PD-L1 inhibition challenges in oral administration, stability, bioavailability, and toxicity.

Bicyclic compounds target GABAA α5 selectively to limit unwanted CNS effects.

High-pressure conversion and column separation produce RGX-365 to address fine dust-induced respiratory inflammation.

A sterile, preservative-free ketamine infusion premix uses pH and packaging control to support 24-month stability.

This formulation case uses solubilizers and stabilizers at pH 2–6 to preserve netupitant potency and limit impurities during storage.

This case uses lipid-encapsulated DNAH5 mRNA to address large-gene delivery and support DNAH5 protein expression for PCD.

This case combines selected 5′ and 3′ UTRs with Cas-encoding RNA for brief, high expression and reduced off-target effects.

This case combines bupropion with reduced dextromethorphan dosing to preserve efficacy while limiting adverse-event risk.

This case uses pediatric Kv7 activators to shift channel activation, regulate neuronal excitability, and reduce seizure severity.

Camsylate salts improve triazolopyrazine solubility and stability for c-Met therapy.

Viral vectors deliver genetic elements into PBMCs to enrich HIV-specific CD4+ T cells while addressing drug toxicity and resistance.

Rifabutin with colistin or cefiderocol boosts sensitivity in MDR A. baumannii strains, including those with rpoB mutations.

This case combines orthosteric and allosteric or interface targeting to inhibit 3CLpro dimerization with additive antiviral effects.

Cosolvents and surfactants form a Type IV lipid system that improves dazucorilant solubility, stability, and oral usability.

This case examines tinostamustine’s dual HDAC inhibition and DNA alkylation approach for cytotoxicity and apoptosis in T-PLL.

See how controlled-release levodopa with carbidopa supports steadier plasma levels, less Off time, and improved motor function.

Fluorescent CuNCs and TMHA stabilize copper, protect neurons, and support detection and targeted treatment of Parkinson’s disease.

This case uses IL-7Rα-binding antibodies and Fc-mediated ADCC to reduce ALL proliferation with less toxicity than chemotherapy.

This case uses a liquid aqueous edaravone solution to avoid infusion burdens and drug-free periods in neurodegenerative care.

Bioreducible poly(β-amino ester) nanoparticles protect siRNA and use glutathione-triggered release for low-dose gene knockdown.

This case combines ERAP2 inhibition with HLA-A29 or HLA-B27 nucleic acids to reduce aberrant antigenic peptide generation.

Banked haematopoietic precursors enable consistent cancer-killing granulocyte therapy.

This case shows how structural variation of cyclic phosphatidic acid derivatives identifies a compound with three signaling activities.

Formula-based lipid particles improve nucleic acid encapsulation and delivery.

This food composition balances low glycine and serine levels with anti-PD-1 therapy to suppress tumors and enhance immune function.

This case uses an α-ketoamide active head in quinolinecarboxamides to strengthen FAP binding for imaging and tumor targeting.

This case uses E3 ligase recruitment and ubiquitination to degrade resistant EGFR mutants beyond ATP-site inhibition.

Substituted imidazopyrimidines target EED to inhibit PRC2 across EZH2 mutation states, addressing potency, stability, and safety tradeoffs.

This case addresses SN-38 solubility and scale-up through Span 20, lipid–albumin encapsulation, and reduced homogenization.

This case uses orally bioavailable ER antagonists with CDK4/6, PIK3CA, or mTOR inhibitors to treat mutant ER cancers.